-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WHX8Pxt0b0edzoiS33x2eOO0Pner/o+NLW90irr7JHa+3+tlWG6LCKdzS23pgqNO
 F5Tn76IluGTsgPxgAMuW+Q==

<SEC-DOCUMENT>0000905729-04-000350.txt : 20040924
<SEC-HEADER>0000905729-04-000350.hdr.sgml : 20040924
<ACCEPTANCE-DATETIME>20040924165614
ACCESSION NUMBER:		0000905729-04-000350
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20040728
FILED AS OF DATE:		20040924
DATE AS OF CHANGE:		20040924

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INTERLEUKIN GENETICS INC
		CENTRAL INDEX KEY:			0001037649
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				943123681
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		135 BEAVER ST
		CITY:			WATHAM
		STATE:			MA
		ZIP:			02452
		BUSINESS PHONE:		1-781-398-0700

	MAIL ADDRESS:	
		STREET 1:		135 BEAVER ST
		CITY:			WATHAM
		STATE:			MA
		ZIP:			02452

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MEDICAL SCIENCE SYSTEMS INC
		DATE OF NAME CHANGE:	19971003

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Alticor Global Holdings Inc.
		CENTRAL INDEX KEY:			0001303680

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23413
		FILM NUMBER:		041045426

	BUSINESS ADDRESS:	
		STREET 1:		7575 FULTON STREET EAST
		CITY:			ADA
		STATE:			MI
		ZIP:			49355-0001
		BUSINESS PHONE:		(616) 787-5221

	MAIL ADDRESS:	
		STREET 1:		7575 FULTON STREET EAST
		CITY:			ADA
		STATE:			MI
		ZIP:			49355-0001
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>primary_doc.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0202</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2004-07-28</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001037649</issuerCik>
        <issuerName>INTERLEUKIN GENETICS INC</issuerName>
        <issuerTradingSymbol>ILGN</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001303680</rptOwnerCik>
            <rptOwnerName>Alticor Global Holdings Inc.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>7575 FULTON STREET EAST</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>ADA</rptOwnerCity>
            <rptOwnerState>MI</rptOwnerState>
            <rptOwnerZipCode>49355-0001</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Series A Preferred Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.3196</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <footnoteId id="F2"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By subsidiaries</value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
        <derivativeHolding>
            <securityTitle>
                <value>Convertible Promissory Notes</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.6392</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <footnoteId id="F3"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By subsidiaries</value>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Not applicable.</footnote>
        <footnote id="F2">On July 28, 2004, the Reporting Person became the ultimate parent corporation of Pyxis Innovations Inc. (&quot;Pyxis&quot;), which owns 5,000,000 shares of the issuer's Series A Preferred Stock.  As of the date of this filing, these shares are convertible into 28,160,200 shares of the issuer's common stock, reflecting a conversion price of $.3196 per share, subject to adjustment as provided in the Certificate of Designations, Preferences and Rights for Series A Perferred Stock.</footnote>
        <footnote id="F3">Pyxis holds notes from the issuer with an aggregate original principal amount of $2,595,336.  The principal amount of the notes, plus accrued interest thereon, is convertible into the issuer's common stock at any time at the option of Pyxis.  These notes are convertible into shares of common stock at a conversion price equal to two times the conversion price of the Series A Preferred Stock in effect at the time of conversion.  As of September 23, 2004, the notes would have been convertible into 4,109,929 shares of the issuer's common stock.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Michael A. Mohr, Vice President and Secretary</signatureName>
        <signatureDate>2004-09-24</signatureDate>
    </ownerSignature>
</ownershipDocument>

</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----